Foundayo reaches US retail pharmacies and telehealth providers

Eli Lilly said on April 9, 2026 that Foundayo (orforglipron), its once-daily oral GLP-1 pill for weight management, is now available in the United States through LillyDirect and telehealth providers, with shipments to retail pharmacies nationwide starting the same day ^[1]. The Food and Drug Administration approved the drug on April 1, 2026 for adults with obesity, or some adults with overweight who also have weight-related medical problems, alongside a reduced-calorie diet and more physical activity ^[1][3].

What it costs

Lilly listed self-pay pricing that starts at $149 per month at the lowest dose ^[1]. People with commercial insurance that covers Foundayo may pay as little as $25 per month using the company's savings card, if they qualify ^[1]. Lilly also said eligible Medicare Part D beneficiaries may be able to get the drug for $50 per month beginning July 1, 2026 ^[1].

The company did not publish a list price or say what self-pay costs at higher doses; the announcement only describes the $149 figure as a starting price at the lowest dose ^[1]. Lilly framed the pricing around a coverage gap it described in the same release: roughly half of Americans with employer-sponsored insurance lack coverage for obesity management medications ^[1].

What the trials showed

Foundayo's approval was backed by the ATTAIN Phase 3 program, which enrolled more than 4,500 people with obesity or overweight across two global registration trials ^[1]. In ATTAIN-1, which randomized 3,127 adults without diabetes over 72 weeks, people on the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4% of body weight, compared with 2.2 pounds (0.9%) on placebo ^[1][3]. Counting everyone assigned to the drug regardless of whether they finished the trial, the average loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo ^[1][3].

ATTAIN-2 enrolled more than 1,600 adults with obesity or overweight plus type 2 diabetes and also showed greater weight reduction than placebo at 72 weeks ^[1][3]. Across doses, Lilly reported reductions in several cardiovascular risk markers, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure ^[1].

Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist, which is why it can be taken at any time of day without the food and water restrictions that apply to peptide-based oral semaglutide ^[1][3]. It comes as tablets in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg strengths, with a step-up schedule spaced at least 30 days apart ^[3]. Orforglipron was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018 ^[1].

Why it matters for patients

For the first time, a GLP-1 weight-loss medicine is available as a pill that does not require fasting or waiting before eating or drinking ^[1][3]. That changes the practical routine for people who have avoided injections or struggled with the timing rules of other oral options, and the retail pharmacy rollout means prescriptions can be filled at a local drugstore rather than only by mail ^[1].

Cost still varies a lot by situation. The $25 figure applies only to people with commercial insurance that already covers the drug and who meet savings-card rules; the $149 figure applies to people paying cash at the lowest dose ^[1]. Lilly has not said how many health plans cover Foundayo at launch, and that information is not yet public.

The label carries a boxed-style warning that Foundayo may cause thyroid tumors, including thyroid cancer, and it should not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[1]. Other serious risks listed include pancreatitis, severe stomach problems, dehydration leading to kidney problems, low blood sugar when combined with insulin or sulfonylureas, gallbladder problems, allergic reactions and aspiration risk during anesthesia ^[1]. The most common side effects are nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas and hair loss ^[1]. Lilly also notes that oral birth control pills may not work as well while taking Foundayo, and that it should not be combined with other GLP-1 medicines ^[1]. Safety and effectiveness in children have not been established ^[1].

What happens next

July 1, 2026 is the date Lilly gave for the $50 monthly option for eligible Medicare Part D beneficiaries ^[1]. Orforglipron is also being studied for type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, hypertension, peripheral artery disease and stress urinary incontinence; those uses are not approved ^[1].